Chi Kyun Yoo, Kim Gyeongmin, Son Jeong Sang, Han Jiyou, Kim Jong-Hoon
Laboratory of Stem Cells and Tissue Regeneration, Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, South Korea.
User Convenience Technology R&D Department, Korea Institute of Industrial Technology (KITECH), Ansan, 15588, South Korea.
Tissue Eng Regen Med. 2025 May 13. doi: 10.1007/s13770-025-00719-8.
Liver fibrosis is a reversible but complex pathological condition associated with chronic liver diseases, affecting over 1.5 billion people worldwide. It is characterized by excessive extracellular matrix deposition resulting from sustained liver injury, often advancing to cirrhosis and cancer. As its progression involves various cell types and pathogenic factors, understanding the intricate mechanisms is essential for the development of effective therapies. In this context, extensive efforts have been made to establish three-dimensional (3D) in vitro platforms that mimic the progression of liver fibrosis.
This review outlines the pathophysiology of liver fibrosis and highlights recent advancements in 3D in vitro liver models, including spheroids, organoids, assembloids, bioprinted constructs, and microfluidic systems. It further assesses their biological relevance, with particular focus on their capacity to reproduce fibrosis-related characteristics.
3D in vitro liver models offer significant advantages over conventional two-dimensional cultures. Although each model exhibits unique strengths, they collectively recapitulate key fibrotic features, such as extracellular matrix remodeling, hepatic stellate cell activation, and collagen deposition, in a physiologically relevant 3D setting. In particular, multilineage liver organoids and assembloids integrate architectural complexity with scalability, enabling deeper mechanistic insights and supporting therapeutic evaluation with improved translational relevance.
3D in vitro liver models represent a promising strategy to bridge the gap between in vitro studies and in vivo realities by faithfully replicating liver-specific architecture and microenvironments. With enhanced reproducibility through standardized protocols, these models hold great potential for advancing drug discovery and facilitating the development of personalized therapies for liver fibrosis.
肝纤维化是一种与慢性肝病相关的可逆但复杂的病理状态,全球有超过15亿人受其影响。其特征是持续的肝损伤导致细胞外基质过度沉积,常进展为肝硬化和癌症。由于其进展涉及多种细胞类型和致病因素,了解其复杂机制对于开发有效疗法至关重要。在此背景下,人们已做出大量努力来建立模拟肝纤维化进展的三维(3D)体外平台。
本综述概述了肝纤维化的病理生理学,并重点介绍了3D体外肝脏模型的最新进展,包括球体、类器官、组装体、生物打印构建体和微流控系统。还进一步评估了它们的生物学相关性,特别关注其再现纤维化相关特征的能力。
3D体外肝脏模型比传统的二维培养具有显著优势。尽管每个模型都有其独特的优势,但它们共同在生理相关的3D环境中概括了关键的纤维化特征,如细胞外基质重塑、肝星状细胞激活和胶原蛋白沉积。特别是,多谱系肝脏类器官和组装体将结构复杂性与可扩展性相结合,能够提供更深入的机制见解,并支持具有更高转化相关性的治疗评估。
3D体外肝脏模型是一种很有前景的策略,通过忠实地复制肝脏特异性结构和微环境来弥合体外研究与体内实际情况之间的差距。通过标准化方案提高了可重复性,这些模型在推进药物发现和促进肝纤维化个性化疗法的开发方面具有巨大潜力。